Abstract 168P
Background
China accounts for half of new esophageal cancer (EC) cases in the world. Limited new therapies were developed during the past decades until the advent of immuno-oncology (IO) in 2020. Yet real-world data is scarce for Chinese EC patients prior to IO approval. This nationwide multicenter retrospective study aimed to describe clinical features and treatment patterns of EC in China to capture baseline treatment landscape as the benchmark before IO approval.
Methods
Patient-level data of patients who initiated first therapy for newly diagnosed EC in 2018 were extracted from a large nationwide database. Information within 6 months after initial anti-tumor treatment were obtained and descriptively summarized.
Results
A total of 3493 EC patients from 14 hospitals in China were included in this study, with mean age of 64.1 years at initial diagnosis. The majority of patients were male (75.7%), squamous cell carcinoma (92.8%), with primary lesion at middle (56.4%) esophagus and living in urban area (53.4%). The proportion of stage I, II and III and IV was 14.9%, 31.6%, 39.2%,14.2%, respectively. Out of the 2138 resectable patients, 1986 underwent upfront radical surgery, while 7.1% patients received neoadjuvant therapy, among which chemotherapy was mainstay preoperative therapy (85.5%). Twenty-three percent of resectable patients had adjuvant therapy, with chemotherapy as the mainstream (75.2%) postoperative regimen. For unresectable early and locally advanced patients, the percentage of radical therapy and palliative therapy was 49.9% and 50.1%, respectively, and definitive chemoradiotherapy was the most common treatment (32.0%). For advanced stage patients, chemotherapy accounted for 84.3% of upfront therapy and taxane-based chemotherapy regimen predominated (66.2%).
Conclusions
In this large observational study, most early-stage and locally advanced patients underwent upfront surgery without preoperative treatment, while for advanced patients, chemotherapy was the primary choice. This is the first real-world study of EC to date with largest sample size reflecting Chinese treatment landscape before IO approval, which will help address unmet needs in clinical practice.
Clinical trial identification
EU PAS Register Number: EUPAS48396, release on 29/07/2022.
Editorial acknowledgement
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. MSD China holding.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure
D.F. Shi, Q. Jing, S. Shi, F. Dong: Financial Interests, Personal, Full or part-time Employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract